Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study

OBJECTIVE: To assess dose-response effects of the anti-CD20 monoclonal antibody ofatumumab on efficacy and safety outcomes in a phase 2b double-blind study of relapsing forms of multiple sclerosis (RMS). METHODS: Patients (n = 232) were randomized to ofatumumab 3, 30, or 60 mg every 12 weeks, ofatum...

Descripción completa

Detalles Bibliográficos
Autores principales: Bar-Or, Amit, Grove, Richard A., Austin, Daren J., Tolson, Jerry M., VanMeter, Susan A., Lewis, Eric W., Derosier, Frederick J., Lopez, Monica C., Kavanagh, Sarah T., Miller, Aaron E., Sorensen, Per S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5957306/
https://www.ncbi.nlm.nih.gov/pubmed/29695594
http://dx.doi.org/10.1212/WNL.0000000000005516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5957306/
https://www.ncbi.nlm.nih.gov/pubmed/29695594
http://dx.doi.org/10.1212/WNL.0000000000005516

Ejemplares similares